TransMedics Group (NASDAQ:TMDX) Shares Climb 3.9% – Still a Buy?

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) traded up 3.9% on Thursday. The company traded as high as $95.78 and last traded at $95.5990. Approximately 107,615 shares were traded during trading, a decline of 89% from the average daily volume of 1,022,576 shares. The stock had previously closed at $92.01.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on TMDX shares. Weiss Ratings upgraded TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, August 31st. Wall Street Zen raised TransMedics Group from a “sell” rating to a “hold” rating in a research note on Saturday, November 7th. Zacks Research upgraded TransMedics Group from a “strong sell” rating to a “hold” rating in a report on Monday, November 2nd. Canaccord Genuity Group upped their target price on TransMedics Group from $95.00 to $120.00 and gave the stock a “buy” rating in a research report on Friday, November 6th. Finally, UBS Group increased their target price on TransMedics Group from $77.00 to $88.00 and gave the stock a “neutral” rating in a report on Monday. Five research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $113.30.

TransMedics Group Price Performance

The company has a debt-to-equity ratio of 1.46, a quick ratio of 4.15 and a current ratio of 4.53. The business has a 50 day simple moving average of $80.04 and a 200-day simple moving average of $92.52. The firm has a market cap of $3.21 billion, a price-to-earnings ratio of 24.94, a P/E/G ratio of 1.70 and a beta of 2.14.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Thursday, November 5th. The company reported $0.51 EPS for the quarter, topping the consensus estimate of $0.30 by $0.21. TransMedics Group had a return on equity of 13.30% and a net margin of 19.85%. The firm had revenue of $203.01 million during the quarter, compared to the consensus estimate of $178.06 million. During the same period in the prior year, the business posted $0.66 earnings per share. The company’s quarterly revenue was up 41.1% compared to the same quarter last year. Equities research analysts expect that TransMedics Group, Inc. will post 1.58 earnings per share for the current year.

Insider Transactions at TransMedics Group

In related news, Director David Weill purchased 1,336 shares of the stock in a transaction that occurred on Friday, September 11th. The stock was acquired at an average cost of $81.63 per share, with a total value of $109,057.68. Following the transaction, the director owned 16,392 shares of the company’s stock, valued at $1,338,078.96. This represents a 8.87% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 6.90% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

Several large investors have recently bought and sold shares of TMDX. Headlands Technologies LLC purchased a new stake in shares of TransMedics Group in the second quarter valued at about $1,634,000. The Manufacturers Life Insurance Company purchased a new position in TransMedics Group during the second quarter worth about $1,140,000. FirstWave Capital Management LLC boosted its holdings in TransMedics Group by 53.9% during the second quarter. FirstWave Capital Management LLC now owns 191,240 shares of the company’s stock worth $12,702,000 after purchasing an additional 66,972 shares during the last quarter. Wellington Management Group LLP boosted its holdings in TransMedics Group by 6.1% during the second quarter. Wellington Management Group LLP now owns 515,973 shares of the company’s stock worth $34,271,000 after purchasing an additional 29,500 shares during the last quarter. Finally, Emerald Investment Advisers LLC bought a new stake in TransMedics Group in the 2nd quarter worth about $2,023,000. 99.67% of the stock is currently owned by institutional investors.

About TransMedics Group

TransMedics Group, Inc. is a medical technology company focused on improving organ transplantation. Its Organ Care System (OCS) is a portable platform that perfuses donor organs with warm, oxygenated blood and nutrients while they are outside the body. The company offers OCS systems for donor hearts, lungs and livers, along with related consumables and services. The company also operates the National OCS Program in the United States, an integrated offering that combines its technology with organ procurement and transportation services.